(22UA) BioNTech SE - Ratings and Ratios

BioNTech SE is a German biotechnology company specializing in the development and commercialization of next-generation immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has established itself as a pioneer in mRNA-based therapies and personalized cancer treatments. Its pipeline includes a diverse range of clinical-stage candidates targeting various solid tumors and cancers, leveraging proprietary mRNA platforms and collaboration partnerships.

BioNTechs oncology pipeline includes multiple candidates in advanced stages of development. BNT111, a melanoma treatment, and BNT113, targeting head and neck squamous cell carcinoma, are both in Phase 2 trials. The company also has several Phase 1/2 and Phase 2 candidates, such as BNT142, BNT151, and BNT122/RO7198457, addressing multiple solid tumors, colorectal cancer, pancreatic ductal adenocarcinoma, and urothelial carcinoma. Additional candidates like BNT211, BNT221, and BNT327 are in earlier stages, focusing on specific tumor types such as CLDN6+ solid tumors and small cell lung cancer. BNT312/GEN1042 and BNT315/GEN1055 are part of collaborations with Genentech, expanding the companys therapeutic reach.

Recent clinical advancements include BNT311/GEN1046 (acasunlimab), which has entered Phase 3 trials for solid tumors, and BNT316/ONC-392, currently in Phase 1/2, 2, and 3 trials for non-small cell lung cancer, ovarian cancer, and prostate cancer. These developments underscore BioNTechs commitment to addressing unmet medical needs in oncology.

From a technical standpoint, BioNTechs stock (XETRA:22UA) shows a declining trend, with SMA 20 (85.17), SMA 50 (96.97), and SMA 200 (98.37) indicating bearish momentum. The average volume of 41,995 shares suggests moderate liquidity. The ATR of 4.29 signals manageable volatility.

Fundamentally, BioNTechs market cap of €20.61 billion reflects its significant valuation despite a P/E ratio of None and a forward P/E of 7.14, suggesting expectations of future profitability. The P/S ratio of 7.49 indicates a premium valuation relative to sales. The RoE of -3.43% highlights ongoing losses, likely tied to R&D investments.